RT Journal Article
SR Electronic
T1 ADVANCING PARKINSON’S DISEASE RESEARCH IN CANADA: THE CANADIAN OPEN PARKINSON NETWORK (C-OPN) COHORT
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.05.10.24307196
DO 10.1101/2024.05.10.24307196
A1 Cressatti, Marisa
A1 Pinilla-Monsalve, Gabriel D.
A1 Blais, Mathieu
A1 Normandeau, Catherine P.
A1 Degroot, Clotilde
A1 Kathol, Iris
A1 Bogard, Sarah
A1 Bendas, Anna
A1 Camicioli, Richard
A1 Dupré, Nicolas
A1 Gan-Or, Ziv
A1 Grimes, David A.
A1 Kalia, Lorraine V.
A1 MacDonald, Penny A.
A1 McKeown, Martin J.
A1 Martino, Davide
A1 Miyasaki, Janis M.
A1 Schlossmacher, Michael G.
A1 Jon Stoessl, A.
A1 Strafella, Antonio P.
A1 Fon, Edward A.
A1 Monchi, Oury
YR 2024
UL http://medrxiv.org/content/early/2024/05/12/2024.05.10.24307196.abstract
AB Background Enhancing the interactions between study participants, clinicians, and investigators is imperative for advancing Parkinson’s disease (PD) research. The Canadian Open Parkinson Network (C-OPN) stands as a nationwide endeavor, connecting the PD community with ten accredited universities and movement disorders research centers spanning –at the time of this analysis– British Columbia, Alberta, Ontario, and Quebec.Objective Our aim is to showcase C-OPN as a paradigm for bolstering national collaboration to accelerate PD research and to provide an initial overview of already collected data sets.Methods The C-OPN database comprises de-identified data concerning demographics, symptoms and signs, treatment approaches, and standardized assessments. Additionally, it collects venous blood-derived biomaterials, such as for analyses of DNA, peripheral blood mononuclear cells (PBMC), and serum. Accessible to researchers, C-OPN resources are available through web-based data management systems for multi-center studies, including REDCap.Results As of November 2023, the C-OPN had enrolled 1,505 PD participants. The male-to-female ratio was 1.77:1, with 83% (n = 1098) residing in urban areas and 82% (n = 1084) having pursued post-secondary education. The average age at diagnosis was 60.2 ± 10.3 years. Herein, our analysis of the C-OPN PD cohort encompasses environmental factors, motor and non-motor symptoms, disease management, and regional differences among provinces. As of April 2024, 32 researchers have utilized C-OPN resources.Conclusions C-OPN represents a national platform promoting multidisciplinary and multisite research that focuses on PD to promote innovation, exploration of care models, and collaboration among Canadian scientists.PLAIN LANGUAGE SUMMARY Teamwork and communication between people living with Parkinson’s disease (PD), doctors, and research scientists is important for improving the lives of those living with this condition. The Canadian Open Parkinson Network (C-OPN) is a Canada-wide initiative, connecting the PD community with ten accredited universities and movement disorders research centers located in –at the time of this analysis– British Columbia, Alberta, Ontario, and Quebec. The aim of this paper is to showcase C-OPN as a useful resource for physician and research scientists studying PD in Canada and around the world, and to provide snapshot of already collected data. The C-OPN database comprises de-identified (meaning removal of any identifying information, such as name or date of birth) data concerning lifestyle, disease symptoms, treatments, and results from standardized tests. It also collects blood samples for further analysis.As of November 2023, C-OPN had enrolled 1,505 PD participants across Canada. Most of the participants were male (64%), living in urban areas (83%), and completed post-secondary education (82%). The average age at diagnosis was 60.2 ± 10.3 years. In this paper, we look at environmental factors, motor and non-motor symptoms, different disease management strategies, and regional differences between provinces. In conclusion, C-OPN represents a national platform that encourages multidisciplinary and multisite research focusing on PD to promote innovation and collaboration among Canadian scientists.Competing Interest StatementJMM has grants from Patient Centered Outcomes Research Institute (2021 to 2023), Parkinson Foundation: PD GENEration (2023 to present), the Canadian Consortium on Neurodegeneration in Aging (2018-present), and Brain Canada (2018 to present). JMM serves as a US delegate of Oxford University Press (2022 to 2026). JMM serves as Vice President of the American Academy of Neurology and is on the Board of Directors of Parkinson Foundation. APS was a past consultant for Hoffman La Roche; received honoraria from GE Health Care Canada LTD, Hoffman La Roche. APS serves on the Board Directors of Parkinson Canada and Canadian Academy Health Sciences. APS is supported by Canadian Institutes of Health Research (CIHR) (PJT173540) and Krembil Rossy Chair program. DAG has received honorariums for speaking from Ipsen and for consulting from Abbvie. DAG is involved in clinical trials via CIHR, Cerevel Therapeutics, Hoffman La Roche, UCB Biopharma, and Bial R&D Investments. DAG has also received grants from CIHR, Parkinson Canada, Brain Canada, Parkinson Research Consortium, EU Joint Programme Neurodegenerative Disease Research, uOBMRI, and NIH. ZGO, LVK, and APS are Editorial Board Members of this journal but were not involved in the peer review process of this article nor had access to any information regarding its peer review. MC, GPM, MB, CPN, CD, IK, SB, AB, RC, ND, PAM, MJM, DM, MGS, AJS, EAF, and OM have no conflicts of interests to report pertaining to this study.Funding StatementThis study was funded by Parkinson Canada and Brain Canada through the Canada Brain Research Fund, with the financial support of Health Canada.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics committee/IRB of the University of Calgary gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.